Guidelines 4.8 & 4.9 – Safety and Monitoring Response of HIF-PHI

Guideline 4.8 – Safety of HIF-PHI:

We suggest that cautious use of HIF-PHI in people with CKD and either known CVD or thrombotic events and consideration of lower dose regimes to reduce rapid rises in Hb. (2C)

Guideline 4.9 – Monitoring Response to HIF-PHI:

We recommend that Hb levels should be monitored every two weeks until the desired Hb target range of 100 to 120 g/L is achieved and stabilised, and every 4 weeks thereafter, or as clinically indicated. (1B)

Rationale

The recommendations are based on current SMPC guidance and the protocols from RCTs.